Tanya Schlemmer
Acute Care · Dallas, TXNPI 1265405344
Payments from drug & device makers
Across 107 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$522
- Novo Nordisk$206
- AstraZeneca$164
- Amgen$132
- Bayer$112
- Pfizer$88
- plus $596 from 18 others
What the payments were for
- Food & beverage$1,821100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 32 | $522 |
| Novo Nordisk | 12 | $206 |
| AstraZeneca | 10 | $164 |
| Amgen | 7 | $132 |
| Bayer | 7 | $112 |
| Pfizer | 4 | $88 |
| E.r. Squibb & Sons, L.L.C. | 5 | $87 |
| Amarin Pharma, Inc. | 4 | $71 |
| Lilly USA, LLC | 4 | $57 |
| Otsuka America Pharmaceutical, Inc. | 2 | $56 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $46 |
| Sumitomo Pharma America, Inc. | 2 | $39 |
| GSK | 2 | $38 |
| Exact Sciences | 2 | $33 |
| Astellas Pharma US Inc | 2 | $29 |
| Novartis | 1 | $21 |
| Johnson & Johnson | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Philips North America LLC | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Merck | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $12 |
| Antares Pharma, Inc. | 1 | $12 |
How this compares
$1,821 in reported general payments places this provider in the 80th percentile of 2,323 acute care providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 17 | $28,394 |
| OzempicSemaglutide | 22 | $27,144 |
| EliquisApixaban | 17 | $25,466 |
| RybelsusSemaglutide | 16 | $15,191 |
| JanuviaSitagliptin Phosphate | 13 | $8,431 |
| SynthroidLevothyroxine Sodium | 13 | $1,402 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $1,345 |
| Rosuvastatin Calcium | 87 | $1,140 |
| Ezetimibe | 31 | $817 |
| Pentoxifylline | 17 | $700 |
| Levothyroxine Sodium | 47 | $656 |
| Telmisartan | 17 | $553 |
| Valsartan | 20 | $409 |
| Olmesartan Medoxomil | 23 | $390 |
| Metoprolol Succinate | 19 | $305 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $206 | $42,33538 claims |
| AstraZenecaFarxiga | $164 | $28,39417 claims |
| PfizerEliquis | $88 | $25,46617 claims |
| MerckJanuvia | $14 | $8,43113 claims |
| AbbVieSynthroid | $522 | $1,40213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,323 acute care providers in Texas.
Other acute care in Dallas
- Jennifer PilotteDallas$232K
- Amanda BradleyDallas$85K
- Martha LibertyDallas$28K
- Rachael SchneiderDallas$20K
- Peter TriporoDallas$15K
- Mario PadillaDallas$13K
- Toni SmithDallas$10K
- Christie MorrisonSan Antonio$225K
- Laura WilsonEl Paso$32K
- Kim HuynhCypress$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.